Sign in
CompletedNo phase

Effect of Urine-guided Hydration on Acute Kidney Injury After CRS-HIPEC

Key facts

Who runs it
Peking University First Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
168 people enrolled
Started
24 Jul 2023
Ended
4 Feb 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Urine-guided hydration
  • Routine hydration
  • Forced administration of furosemide
  • Routine administration of furosemide
Record updated
19 March 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age ≥18 years
  • Diagnosed as pseudomyxoma peritonei, scheduled for cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy under general anesthesia
  • At least 14 days since the last treatment of chemotherapy, radiotherapy, or immunotherapy
  • Consent to participate in this study

Who cannot take part

  • Requirement of vasopressors to maintain blood pressure before surgery
  • Persistent preoperative atrial fibrillation, or new-onset cardiovascular event (acute coronary syndrome, stroke, or congestive heart failure) in the past 3 months
  • Known furosemide hypersensitivity
  • Chronic kidney disease stage 5 or requirement of renal replacement therapy
  • Other conditions that are considered unsuitable for the study participation

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Acute renal injury (AKI) is a common complication after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), and is associated with worse outcomes. Available evidences show that maintaining intraoperative urine output ≥ 200 ml/h by fluid and furosemide administration may reduce the incidence of AKI in patients undergoing cardiopulmonary bypass. The investigators hypothesize that, for patients undergoing CRS-HIPEC, intraoperative urine-volume guided hydration may also reduce the incidence of postoperative AKI.

The 2 groups in the trial

  • Urine-guided hydrationTreatment being tested

    The target is to maintain urine output at 200 ml/h (3 ml/kg/h) or higher by intravenous injection/infusion of furosemide throughout surgery. That is, a loading dose of 20 mg is injected at the beginning of surgery; if the urine output does not reach the target value, furosemide will be continuously infused at 10 mg/h until the end of the surgery as needed, with a maximum cumulative dose not exceeding 250 mg. Intravenous hydration is performed to balance urine output and to maintain the SVV≤10%.

    Treatment: Urine-guided hydration and Forced administration of furosemide

  • Routine hydrationExisting treatment, for comparison

    The target is to maintain urine output at 0.5 ml/kg/h or higher as per current medical practice. That is, furosemide is only administered when clinically necessary or at the discretion of attending anesthesiologists. Intravenous hydration is performed to maintain the SVV≤10%.

    Treatment: Routine hydration and Routine administration of furosemide

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Urine-guided Intraoperative Hydration on the Incidence of Postoperative Acute Kidney Injury and Long-term Outcomes in Patients With Pseudomyxoma Peritonei Receiving CRS-HIPEC: a Prospective, Randomized, Controlled Trial
Record updated
19 March 2025